Please assess the completion status of the following clinical trial:

Trial Title: Pain in Patients With Dementia and Behavioural Disturbances

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 65 and older~* Residing in the NHs for at least 4 weeks~* Dementia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric Association 1994), FAST score \> 4 (Hughes 1982).~* Clinically relevant BPSD, operationally defined as CMAI score ≥ 39 or higher or/and at least one week history of agitation or aggression (Koss 1997).~* Written, informed consent provided by the participant (if they have capacity) or assent (if they do not have capacity) and a written proxy informed consent from a legally authorized representative empowered to make health-related decisions for the potential study participant.~Exclusion Criteria:~* Clinician responsible for care, or study clinician considers that the patient suffers from any physical condition, which would make participation in the trial distressing or likely to increase suffering~* Advanced severe medical disease/disorder with expected survival less than 6 months or that could interfere with participation~* Psychosis or other severe mental disorder prior to dementia diagnosis;~* Severe aggression (≥8) on item 3 of the NPI subscale, with aggression as the predominant symptom~* Schizophrenia, schizoaffective disorder and bipolar disorder~* Uncontrolled epilepsy~* Severe liver impairment~* Renal failure, as measured by or equivalent to an estimated creatinine clearance of \< 50mL/min/1.73m,~* Severe injury or anaemia (Hb \< 8.5 mmol/l), comatose state, current enrolment in another experimental protocol.~* Known allergy or adverse reaction to Paracetamol, Morphine ret, Buprenorphine plaster or pregabalin

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment as usual (Type: NO_INTERVENTION): Control group
- Paracetamol (Type: ACTIVE_COMPARATOR): Intervention group
- Morphine (Type: ACTIVE_COMPARATOR): Intervention group, individual pain treatment
- Buprenorphine plaster (Type: ACTIVE_COMPARATOR): Intervention group, individual pain treatment
- Pregabalin (Type: ACTIVE_COMPARATOR): Intervention group, individual pain treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).